AKBA Q2 2017 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M

Gross Profit

-$15M-53.4% margin

Operating Income

-$22M-77.6% margin

Net Income

-$22M-75.4% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

+36.7%

Cash Flow

Operating Cash Flow

$24M

Free Cash Flow

$24M

Stock-Based Comp.

-$907,000

Balance Sheet

Total Assets

$337M

Total Liabilities

$280M

Stockholders' Equity

$57M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$0	—
Gross Profit	-$15M	-$31M	+50.7%
Operating Income	-$22M	-$36M	+38.8%
Net Income	-$22M	-$36M	+39.9%